668 related articles for article (PubMed ID: 31870950)
21. 5-MTHF enhances the portal pressure reduction achieved with propranolol in patients with cirrhosis: A randomized placebo-controlled trial.
Vukotic R; Di Donato R; Roncarati G; Simoni P; Renzulli M; Gitto S; Schepis F; Villa E; Berzigotti A; Bosch J; Andreone P
J Hepatol; 2023 Oct; 79(4):977-988. PubMed ID: 37482222
[TBL] [Abstract][Full Text] [Related]
22. Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension.
Afdhal N; Everson GT; Calleja JL; McCaughan GW; Bosch J; Brainard DM; McHutchison JG; De-Oertel S; An D; Charlton M; Reddy KR; Asselah T; Gane E; Curry MP; Forns X
J Viral Hepat; 2017 Oct; 24(10):823-831. PubMed ID: 28295923
[TBL] [Abstract][Full Text] [Related]
23. Antiviral therapy reduces portal pressure in patients with cirrhosis due to HBeAg-negative chronic hepatitis B and significant portal hypertension.
Manolakopoulos S; Triantos C; Theodoropoulos J; Vlachogiannakos J; Kougioumtzan A; Papatheodoridis G; Tzourmakliotis D; Karamanolis D; Burroughs AK; Archimandritis A; Raptis S; Avgerinos A
J Hepatol; 2009 Sep; 51(3):468-74. PubMed ID: 19616339
[TBL] [Abstract][Full Text] [Related]
24. Prognostic performance of non-invasive tests for portal hypertension is comparable to that of hepatic venous pressure gradient.
Jachs M; Hartl L; Simbrunner B; Semmler G; Balcar L; Hofer BS; Schwarz M; Bauer D; Stättermayer AF; Pinter M; Trauner M; Reiberger T; Mandorfer M
J Hepatol; 2024 May; 80(5):744-752. PubMed ID: 38218352
[TBL] [Abstract][Full Text] [Related]
25. Effects of atorvastatin on portal hemodynamics and clinical outcomes in patients with cirrhosis with portal hypertension: a proof-of-concept study.
Bishnu S; Ahammed SM; Sarkar A; Hembram J; Chatterjee S; Das K; Dhali GK; Chowdhury A; Das K
Eur J Gastroenterol Hepatol; 2018 Jan; 30(1):54-59. PubMed ID: 29099421
[TBL] [Abstract][Full Text] [Related]
26. Three months of simvastatin therapy vs. placebo for severe portal hypertension in cirrhosis: A randomized controlled trial.
Pollo-Flores P; Soldan M; Santos UC; Kunz DG; Mattos DE; da Silva AC; Marchiori RC; Rezende GF
Dig Liver Dis; 2015 Nov; 47(11):957-63. PubMed ID: 26321186
[TBL] [Abstract][Full Text] [Related]
27. Emricasan, a pan-caspase inhibitor, improves survival and portal hypertension in a murine model of common bile-duct ligation.
Eguchi A; Koyama Y; Wree A; Johnson CD; Nakamura R; Povero D; Kneiber D; Tameda M; Contreras P; Spada A; Feldstein AE
J Mol Med (Berl); 2018 Jun; 96(6):575-583. PubMed ID: 29728708
[TBL] [Abstract][Full Text] [Related]
28. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials.
Harrison SA; Wong VW; Okanoue T; Bzowej N; Vuppalanchi R; Younes Z; Kohli A; Sarin S; Caldwell SH; Alkhouri N; Shiffman ML; Camargo M; Li G; Kersey K; Jia C; Zhu Y; Djedjos CS; Subramanian GM; Myers RP; Gunn N; Sheikh A; Anstee QM; Romero-Gomez M; Trauner M; Goodman Z; Lawitz EJ; Younossi Z; ;
J Hepatol; 2020 Jul; 73(1):26-39. PubMed ID: 32147362
[TBL] [Abstract][Full Text] [Related]
29. Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study.
Harrison SA; Alkhouri N; Davison BA; Sanyal A; Edwards C; Colca JR; Lee BH; Loomba R; Cusi K; Kolterman O; Cotter G; Dittrich HC
J Hepatol; 2020 Apr; 72(4):613-626. PubMed ID: 31697972
[TBL] [Abstract][Full Text] [Related]
30. Thromboelastometry in patients with advanced chronic liver disease stratified by severity of portal hypertension.
Raeven P; Baron-Stefaniak J; Simbrunner B; Stadlmann A; Schwabl P; Scheiner B; Schaden E; Eigenbauer E; Quehenberger P; Mandorfer M; Baron DM; Reiberger T
Hepatol Int; 2020 Dec; 14(6):1083-1092. PubMed ID: 33000389
[TBL] [Abstract][Full Text] [Related]
31. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis.
Ripoll C; Groszmann R; Garcia-Tsao G; Grace N; Burroughs A; Planas R; Escorsell A; Garcia-Pagan JC; Makuch R; Patch D; Matloff DS; Bosch J;
Gastroenterology; 2007 Aug; 133(2):481-8. PubMed ID: 17681169
[TBL] [Abstract][Full Text] [Related]
32. The impact of emricasan on chronic liver diseases: current data.
Lekakis V; Cholongitas E
Clin J Gastroenterol; 2022 Apr; 15(2):271-285. PubMed ID: 35000120
[TBL] [Abstract][Full Text] [Related]
33. Agreement between wedged hepatic venous pressure and portal pressure in non-alcoholic steatohepatitis-related cirrhosis.
Ferrusquía-Acosta J; Bassegoda O; Turco L; Reverter E; Pellone M; Bianchini M; Pérez-Campuzano V; Ripoll E; García-Criado Á; Graupera I; García-Pagán JC; Schepis F; Senzolo M; Hernández-Gea V
J Hepatol; 2021 Apr; 74(4):811-818. PubMed ID: 33068638
[TBL] [Abstract][Full Text] [Related]
34. Randomised clinical study: acute effects of metformin versus placebo on portal pressure in patients with cirrhosis and portal hypertension.
Rittig N; Aagaard NK; Villadsen GE; Sandahl TD; Jessen N; Grønbaek H; George J
Aliment Pharmacol Ther; 2021 Aug; 54(3):320-328. PubMed ID: 34165199
[TBL] [Abstract][Full Text] [Related]
35. Norfloxacin treatment for clinically significant portal hypertension: results of a randomised double-blind placebo-controlled crossover trial.
Kemp W; Colman J; Thompson K; Madan A; Vincent M; Chin-Dusting J; Kompa A; Krum H; Roberts S
Liver Int; 2009 Mar; 29(3):427-33. PubMed ID: 18673434
[TBL] [Abstract][Full Text] [Related]
36. Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis.
Lens S; Alvarado-Tapias E; Mariño Z; Londoño MC; LLop E; Martinez J; Fortea JI; Ibañez L; Ariza X; Baiges A; Gallego A; Bañares R; Puente A; Albillos A; Calleja JL; Torras X; Hernández-Gea V; Bosch J; Villanueva C; Forns X; García-Pagán JC
Gastroenterology; 2017 Nov; 153(5):1273-1283.e1. PubMed ID: 28734831
[TBL] [Abstract][Full Text] [Related]
37. Effects of Sapropterin on Portal and Systemic Hemodynamics in Patients With Cirrhosis and Portal Hypertension: A Bicentric Double-Blind Placebo-Controlled Study.
Reverter E; Mesonero F; Seijo S; Martínez J; Abraldes JG; Peñas B; Berzigotti A; Deulofeu R; Bosch J; Albillos A; García-Pagán JC
Am J Gastroenterol; 2015 Jul; 110(7):985-92. PubMed ID: 26077176
[TBL] [Abstract][Full Text] [Related]
38. The relationship between portal hypertension and portal hypertensive gastropathy.
Marrache MK; Bou Daher H; Rockey DC
Scand J Gastroenterol; 2022 Mar; 57(3):340-344. PubMed ID: 34904513
[TBL] [Abstract][Full Text] [Related]
39. Plasma Nogo-A and placental growth factor levels are associated with portal hypertension in patients with liver cirrhosis.
Gelman S; Salteniene V; Pranculis A; Skieceviciene J; Zykus R; Petrauskas D; Kupcinskas L; Canbay A; Link A; Kupcinskas J
World J Gastroenterol; 2019 Jun; 25(23):2935-2946. PubMed ID: 31249451
[TBL] [Abstract][Full Text] [Related]
40. Damping index of Doppler hepatic vein waveform to assess the severity of portal hypertension and response to propranolol in liver cirrhosis: a prospective nonrandomized study.
Kim MY; Baik SK; Park DH; Lim DW; Kim JW; Kim HS; Kwon SO; Kim YJ; Chang SJ; Lee SS
Liver Int; 2007 Oct; 27(8):1103-10. PubMed ID: 17845539
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
